Get the Stockscreener App
3.615
0.27%
-0.025
Rocket Pharmaceuticals Inc stock is traded at $3.615, with a volume of 945.95K.
It is down -0.27% in the last 24 hours and down -0.27% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$3.64
Open:
$3.61
24h Volume:
945.95K
Relative Volume:
0.29
Market Cap:
$394.73M
Revenue:
-
Net Income/Loss:
$-209.38M
P/E Ratio:
-1.9262
EPS:
-1.8768
Net Cash Flow:
$-179.81M
1W Performance:
-5.96%
1M Performance:
-0.27%
6M Performance:
+14.51%
1Y Performance:
-45.12%
1-Day Range:
$3.54
$3.65
1-Week Range:
$3.53
$3.96
52-Week Range:
$2.19
$7.14
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.615 | 397.46M | 0 | -209.38M | -179.81M | -1.8768 |
VRTX
Vertex Pharmaceuticals Inc
|
454.04 | 113.78B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
720.21 | 75.84B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
790.78 | 50.55B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.63 | 38.99B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
315.72 | 32.69B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-20-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
TradingKey - TradingKey
Rocket Pharmaceuticals chief commercial officer sells $67,740 in stock By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals chief commercial officer sells $67,740 in stock - Investing.com India
Rocket Pharmaceuticals (RCKT) insider sale covers RSU tax obligations - Stock Titan
Rocket Pharmaceuticals pursues gene therapy advances at Heart Failure 26 to accelerate early diagnosis - Traders Union
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus - The Globe and Mail
RCKT Maintained by Chardan Capital -- Price Target Remains $11 - GuruFocus
RCKT SEC FilingsRocket Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
CCORF Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says - Moomoo
Rocket Pharmaceuticals targets innovation in rare cardiovascular gene therapy at ASGCT event - Traders Union
Rocket Pharmaceuticals Reports Q1 2026 Results: KRESLADI FDA Approval, $180M PRV Sale, and Cash Runway to 2028 - Minichart
Wedbush Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Needham Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo
Rocket Pharmaceuticals: Q1 Earnings Snapshot - theheraldreview.com
RCKT Stock Price, Quote & Chart | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
Rocket Pharmaceuticals reports Q1 2026 net loss $47.6M, cash $144.4M and PRV sale extends runway - TradingView
Rocket Pharmaceuticals (NASDAQ: RCKT) wins KRESLADI nod, sells $180M PRV - Stock Titan
Rocket Pharma (NASDAQ: RCKT) wins first approval, plans $180M PRV sale - Stock Titan
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress - The Joplin Globe
[144] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
MSN Money - MSN
Number of shareholders of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKT - TradingView
Rocket Pharmaceuticals Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
RCKT Technical Analysis | Trend, Signals & Chart Patterns | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pe - The National Law Review
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Rocket Pharmaceuticals (RCKT) and Cullinan Management (CGEM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $9 - Moomoo
US premarket movers: Argan, Rocket Pharmaceuticals, Unity - MSN
LifeSci Capital Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Rocket Pharmaceuticals sells priority review voucher for $180M - Investing.com UK
Leerink raises Rocket Pharmaceuticals stock price target on PRV sale By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Rocket Pharmaceuticals (RCKT) Enhances Financial Stability Throu - GuruFocus
Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway - TipRanks
Rocket Pharmaceuticals to Sell Rare Pediatric Priority Review Voucher for $180 Million - TradingView
$180M PRV sale extends Rocket Pharmaceuticals (RCKT) cash runway to 2028 - Stock Titan
Rocket Pharmaceuticals sells priority review voucher for $180M By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher - The Joplin Globe
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action - TMX Newsfile
Rocket Pharmaceuticals (RCKT) launches employee option exchange program - Stock Titan
Rocket Pharma wins FDA nod for gene therapy (update) - MSN
RCKTW Rocket quarterly earnings metrics not yet public as investors wait for management to share key operational updates.Real Trader Network - Xã Thanh Hà
RCKT (Rocket Pharmaceuticals Inc.) reports narrower Q4 2025 loss than analyst projections, shares tick up modestly after results.Earnings Analysis - Cổng thông tin điện tử tỉnh Tây Ninh
Lifesci Capital Has Pessimistic Outlook of RCKT Q1 Earnings - MarketBeat
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):